Cargando…

Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine

BACKGROUND: The sexual stages of Plasmodium falciparum are responsible for the spread of the parasite in malaria endemic areas. The cysteine-rich Pfs48/45 protein, exposed on the surface of sexual stages, is one of the most advanced antigens for inclusion into a vaccine that will block transmission....

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Susheel K., Roeffen, Will, Mistarz, Ulrik H., Chourasia, Bishwanath Kumar, Yang, Fen, Rand, Kasper D., Sauerwein, Robert W., Theisen, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452637/
https://www.ncbi.nlm.nih.gov/pubmed/28569168
http://dx.doi.org/10.1186/s12934-017-0710-0
_version_ 1783240473791430656
author Singh, Susheel K.
Roeffen, Will
Mistarz, Ulrik H.
Chourasia, Bishwanath Kumar
Yang, Fen
Rand, Kasper D.
Sauerwein, Robert W.
Theisen, Michael
author_facet Singh, Susheel K.
Roeffen, Will
Mistarz, Ulrik H.
Chourasia, Bishwanath Kumar
Yang, Fen
Rand, Kasper D.
Sauerwein, Robert W.
Theisen, Michael
author_sort Singh, Susheel K.
collection PubMed
description BACKGROUND: The sexual stages of Plasmodium falciparum are responsible for the spread of the parasite in malaria endemic areas. The cysteine-rich Pfs48/45 protein, exposed on the surface of sexual stages, is one of the most advanced antigens for inclusion into a vaccine that will block transmission. However, clinical Pfs48/45 sub-unit vaccine development has been hampered by the inability to produce high yields of recombinant protein as the native structure is required for the induction of functional transmission-blocking (TB) antibodies. We have investigated a downstream purification process of a sub-unit (R0.6C) fragment representing the C-terminal 6-Cys domain of Pfs48/45 (6C) genetically fused to the R0 region (R0) of asexual stage Glutamate Rich Protein expressed in Lactococcus lactis. RESULTS: A series of R0.6C fusion proteins containing features, which aim to increase expression levels or to facilitate protein purification, were evaluated at small scale. None of these modifications affected the overall yield of recombinant protein. Consequently, R0.6C with a C-terminal his tag was used for upstream and downstream process development. A simple work-flow was developed consisting of batch fermentation followed by two purification steps. As such, the recombinant protein was purified to homogeneity. The composition of the final product was verified by HPLC, mass spectrometry, SDS-PAGE and Western blotting with conformation dependent antibodies against Pfs48/45. The recombinant protein induced high levels of functional TB antibodies in rats. CONCLUSIONS: The established production and purification process of the R0.6C fusion protein provide a strong basis for further clinical development of this candidate transmission blocking malaria vaccine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-017-0710-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5452637
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54526372017-06-02 Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine Singh, Susheel K. Roeffen, Will Mistarz, Ulrik H. Chourasia, Bishwanath Kumar Yang, Fen Rand, Kasper D. Sauerwein, Robert W. Theisen, Michael Microb Cell Fact Research BACKGROUND: The sexual stages of Plasmodium falciparum are responsible for the spread of the parasite in malaria endemic areas. The cysteine-rich Pfs48/45 protein, exposed on the surface of sexual stages, is one of the most advanced antigens for inclusion into a vaccine that will block transmission. However, clinical Pfs48/45 sub-unit vaccine development has been hampered by the inability to produce high yields of recombinant protein as the native structure is required for the induction of functional transmission-blocking (TB) antibodies. We have investigated a downstream purification process of a sub-unit (R0.6C) fragment representing the C-terminal 6-Cys domain of Pfs48/45 (6C) genetically fused to the R0 region (R0) of asexual stage Glutamate Rich Protein expressed in Lactococcus lactis. RESULTS: A series of R0.6C fusion proteins containing features, which aim to increase expression levels or to facilitate protein purification, were evaluated at small scale. None of these modifications affected the overall yield of recombinant protein. Consequently, R0.6C with a C-terminal his tag was used for upstream and downstream process development. A simple work-flow was developed consisting of batch fermentation followed by two purification steps. As such, the recombinant protein was purified to homogeneity. The composition of the final product was verified by HPLC, mass spectrometry, SDS-PAGE and Western blotting with conformation dependent antibodies against Pfs48/45. The recombinant protein induced high levels of functional TB antibodies in rats. CONCLUSIONS: The established production and purification process of the R0.6C fusion protein provide a strong basis for further clinical development of this candidate transmission blocking malaria vaccine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-017-0710-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-31 /pmc/articles/PMC5452637/ /pubmed/28569168 http://dx.doi.org/10.1186/s12934-017-0710-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Singh, Susheel K.
Roeffen, Will
Mistarz, Ulrik H.
Chourasia, Bishwanath Kumar
Yang, Fen
Rand, Kasper D.
Sauerwein, Robert W.
Theisen, Michael
Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
title Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
title_full Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
title_fullStr Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
title_full_unstemmed Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
title_short Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
title_sort construct design, production, and characterization of plasmodium falciparum 48/45 r0.6c subunit protein produced in lactococcus lactis as candidate vaccine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452637/
https://www.ncbi.nlm.nih.gov/pubmed/28569168
http://dx.doi.org/10.1186/s12934-017-0710-0
work_keys_str_mv AT singhsusheelk constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT roeffenwill constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT mistarzulrikh constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT chourasiabishwanathkumar constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT yangfen constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT randkasperd constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT sauerweinrobertw constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine
AT theisenmichael constructdesignproductionandcharacterizationofplasmodiumfalciparum4845r06csubunitproteinproducedinlactococcuslactisascandidatevaccine